Skip to main content
. 2022 Nov 30;23(23):15046. doi: 10.3390/ijms232315046

Figure 2.

Figure 2

Percentage (%) of neutralizing activity to all SARS-CoV-2 VOCs in immunocompetent (ICs) healthy subjects (n = 11) after the Pfizer-BioNTech BNT162b2 mRNA-based vaccination. IgG neutralizing potential was evaluated three weeks (T2), as well as three (T3) and six months (T4), after the third booster dose. The time point T4 includes vaccinated subjects who contracted SARS-CoV-2 infection during the follow-up (n = 5), indicated as SARS-CoV-2 (+) (red dots), whereas uninfected subjects (n = 6) are indicated as SARS-CoV-2 (−) (white dots). The SARS-CoV-2-specific IgG neutralization ability against the SARS-CoV-2 wild type (A), alfa UK (B), beta (C), gamma (D), delta (E), and omicron (F). The dotted lines correspond to the cutoff level (>20%). The significance was determined using the Mann–Whitney test and t-tests; * p < 0.0332; ** p < 0.0021.